Grail (NASDAQ: GRAL) shares surged 14% this week following a positive reception to its first-quarter earnings report and anticipation of its upcoming presentation at the American Society of Clinical Oncology (ASCO) meeting. Despite this rebound, the stock remains down nearly 28% year-to-date due to disappointing results from a significant trial with England’s National Health Service, which failed to meet its primary endpoint of reducing late-stage cancers with its Galleri multi-cancer early detection test.
The market’s initial skepticism stemmed from concerns over FDA approval and potential insurance coverage for Galleri. However, recent developments indicate a substantial increase in early-stage cancer detections, which could mitigate some worries. Grail’s test volume has exceeded expectations, growing 50% year-over-year, contributing to a 28% revenue increase in the first quarter.
Investors should closely monitor the ASCO presentation, as the detailed trial results could significantly influence market sentiment and Grail’s future prospects.
Source: fool.com